Posted on

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

07/11/2022

— Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months —

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”). This DMT study, which is the largest to date, is expected to accelerate the clinical development path of CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months. The Company previously announced details of the Acquisition on June 7, 2022.

“With the closing of this transaction we are well on our way to advancing CYB004 through Phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule,”said Doug Drysdale, Chief Executive Officer of Cybin. “Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.”

The Company paid a purchase price of CDN$1,000,000 in relation to the Acquisition. Up to an additional CDN$480,000 is payable for consulting services to be provided by Entheon for up to twelve months following the closing of the Acquisition. In connection with the Acquisition, Cybin IRL Limited has also entered into a data license agreement with Entheon that permits Entheon to access certain data to support the Entheon IQ program.

About the CYB004-E Study
The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of a target-controlled intravenous infusion of DMT in healthy smokers.

Primary Objectives:

  • evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes;
  • characterize the PK of a single dose DMT administered continuously over 90 minutes;
  • characterize the PD of a single dose DMT administered continuously over 90 minutes; and,
  • establish the minimum DMT dose required to produce a psychedelic effect.

Pending results from the CYB004-E study, Cybin plans to evaluate CYB004 delivered via intravenous (“IV”) and via inhalation to determine the clinical path forward. Based on preclinical results reported by Cybin in April 2022, inhaled CYB004 demonstrated:

  • approximately 2000% improved bioavailability compared with orally administered DMT, which is known to have limited to no oral bioavailability;
  • approximately 41% improved bioavailability compared with inhaled DMT;
  • approximately 300% longer duration of effect when compared with IV DMT, indicating potential to extend therapeutic window; and,
  • rapid onset of effect and similar low variability equivalent to IV DMT.

CYB004 is a new chemical entity for which a patent was issued by the U.S. Patent and Trademark Office in February 2022. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. The composition of matter patent is expected to expire in 2041 before consideration of any patent term extensions.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Cautionary Notes and Forward-Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe,” “expect,” “aim,” “intend,” “plan,” “continue,” “will,” “may,” “would,” “anticipate,” “estimate,” “forecast,” “predict,” “project,” “seek,” “should” or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders, the Company’s expectation that the Acquisition will accelerate the CYB004 timeline and the Company’s expectations and objectives regarding the results of the CYB004-E study.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company’s management’s discussion and analysis for the year ended March 31, 2022 and the Company’s listing statement dated November 9, 2020, which are available under the Company’s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor & Media:
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com – or – media@cybin.comSource: Cybin Inc.

Posted on

Children took ayahuasca in ancient Incan ritual

Ritual drug use during Inca human sacrifices on Ampato mountain (Peru): Results of a toxicological analysis

A new study suggests that children in the Incan empire took psychedelics to ease stress before being sacrificed.

Archaeologists discovered the 500 year old remains of two Incan children who were sacrificed as part of a ritual called capacocha.

Capacocha was a common ceremony performed to appease the gods for a variety of purposes, such as to prevent natural disasters.

Toxicology samples revealed that the children, who were around the age of 6, consumed coca leaf and ayahuasca in the final weeks of their lives.

According to the study authors, “the Incas may have consciously used the antidepressant properties of (ayahuasca) to reduce the anxiety and depressive states of the victims.”

PDF of article

Posted on

Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease

Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease

May 26, 2022 07:25 AM Eastern Daylight Time

TORONTO–(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that a third Phase II clinical trial for its BMND08 candidate based on 5-Methoxy-N,N-dimethyltryptamine (“5-MeO-DMT”) for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment has been approved by the Argentinian Institutional Review Board.

“As we continue to move forward with our efforts in identifying indications where we can provide significant improvement in patients suffering from mental health, we are more than pleased to announce the approval of a Phase II clinical trial for our BMND08 novel drug candidate which may allow us to address a new line of development to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment,” commented Alejandro Antalich, CEO of Biomind Labs.

“Since our inception, neurodegenerative diseases were on the list of indications we wanted to tackle. We can now address such indications using a novel approach that uses a fast-acting psychedelic molecule capable of providing relief to certain mood states when Alzheimer’s disease first appears in patients. After a thorough analysis on the potential benefit of using a psychedelic molecule to alleviate certain symptoms in Alzheimer’s patients, we concluded that the most suitable candidate from our portfolio was BMND08, an oral formulation of 5-MeO-DMT.”

“Given the significant morbidity rate associated with Alzheimer’s disease such as agitation, apathy, sleep disturbances and anxiety, it became clear to us that novel approaches to treat Alzheimer’s-type cognitive impairment are urgently needed. The Phase II clinical trial will test Biomind’s psychiatry intervention-based model, allowing a rapid and feasible merge of fast-acting psychedelic medicines into clinical practices already in existence.”

“It is an honour for us to be working together with Neuroscientist Dr. Martín A. Bruno and a highly professional interdisciplinary medical team who will be in charge of conducting this Phase II clinical trial.”

“While the current practice guidelines consistently refer to the management of symptoms as central to the treatment of Alzheimer’s disease, the lack of established effective treatments continues to motivate us to generate novel therapeutic solutions”, concluded Antalich.

About Biomind Labs Inc. 

Biomind Labs is a biotech research and development company aimed at transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind Labs is developing novel pharmaceutical formulations of the main psychedelic molecules, N,N-Dimethyltryptamine, 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind Labs’ focus is to provide patients access to affordable and modern-day treatments.

Cautionary Note Regarding Forward-Looking Statements 

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this document include, among others, statements relating to the Company’s ability to scientifically harness the medicinal power of psychedelic molecules to treat patients suffering from neurological and psychiatric disorders, any timeframes and possible results of the Phase II clinical trial of the Company’s novel drug candidate BMND08, including but not limited to its ability to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment and to provide relief to certain mood states when Alzheimer’s disease first appears in patients, the Company’s rapid and feasible merge of fast-acting psychedelic medicines into clinical practices already in existence, the Company’s ability to provide patients access to affordable and modern-day treatments, and other statements that are not historical facts.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (b) compliance with extensive government regulation; (c) domestic and foreign laws and regulations could adversely affect the Company’s business and results of operations; (d) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company’s securities, regardless of its operating peers; (e) adverse changes in the public perception of tryptamine-based treatments and psychedelic-based therapies; (f) the impact of COVID-19; and (g) general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding tryptamine-based treatments, psychedelic-based therapies or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not yet completed commercial clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in commercial clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Posted on

Toad venom for Grandma

Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease

Could Alzheimer’s patients benefit from one of the most powerful psychedelics? 

Biomind Labs (BMND) will find out in an upcoming study.

The Phase 2 trial, which was just approved by the Argentinian Institutional Review Board, will see if 5-MeO-DMT (a psychedelic found in the venom of the Sonoran Desert toad) can ease depression and anxiety in patients with Alzheimer’s disease.

PDF of article

Posted on

LSD reduces anxiety for 4 months

MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

MindMed’s collaborators at University Hospital Basel studied the effect of two high doses of LSD (200μg) on patients with anxiety disorders.

They found that 65% of subjects had significant reductions in anxiety scores for 16 weeks after the treatments.

Like many other studies have found, mystical experiences were significantly correlated with long-term therapeutic benefits.

PDF of article

Posted on

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-related Mental Wellness Challenges

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-related Mental Wellness Challenges

ATMA signs non-binding Letters of Intent to access over 10 clinical sites across Canada in collaboration on the largest psilocybin trial to date.

CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin Clinical Trial to Health Canada today. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in healthcare professionals, as well as analyzing healthcare professionals’ firsthand evaluation of the effectiveness of psilocybin psychotherapy in application.

The primary objective of the trial is to assess the capacity of psilocybin to improve the overall mental health of healthcare providers. While enduring the pandemic has been difficult for all Canadians, healthcare providers have had the immense challenge of helping patients cope with the both the direct and indirect physical and psychological burdens of COVID-19. Using a variety of self-administered tests, including the Quick Inventory of Depressive Symptomatology Self-report 16-item (QIDS-SR16), the Generalized Anxiety Disorder 7-item (GAD-7), and the Burnout Assessment Tool (BAT), healthcare providers will assess their anxiety, depression, and occupational burnout levels before and after consuming psilocybin under the guidance of a licenced medical practitioner. The outcome of this objective will provide real-world data as to the effectiveness of psilocybin. As a secondary exploratory objective, participants will complete an assessment of their psilocybin experience to inform the potential utility of psilocybin in a clinical setting, from the perspective of a healthcare provider.

While an N-500 trial is an enormous undertaking, it is necessary in order to assess the efficacy of psilocybin in treating healthcare professionals struggling with mental health issues during and post-COVID-19, especially therapists who embody the role of ‘the healer’.  Further, by experiencing the efficacious effects of psilocybin firsthand, therapists will be able to offer experiential insights into psilocybin-assisted therapy, thus providing valuable contributions to the future of this field. When combined with psychotherapy, therapists may begin to develop an appreciation of psilocybin’s usefulness in other applications of treatment-resistant mental illness.  

In addition to the primary and secondary outcomes of this Phase II trial, this trial represents an opportunity unlike any other; many participants will be therapists that have previous training in psychedelic medicine, or are undergoing an experiential journey in combination with a psilocybin-assisted therapy training program. ATMA will be running its Psilocybin-assisted Therapy Training Program concurrent to this trial, allowing for the cross participation of healthcare professionals interested in pursuing the path of psychedelic-assisted therapy in the near future. Healthcare professionals will be able to participate as test subjects, facilitators, or both.  For more on ATMA’s training programs, visit https://academy.atmajourney.com/

David Harder, ATMA Co-CEO, explains that “the need for qualified, certified therapists is becoming increasingly evident as we see that these medicines must be given in protocols of pre- and post-treatment counselling. Understanding the holistic nature of psilocybin therapy may prove more effective when the training includes an experiential component.” The clinical trial and Psilocybin-assisted Therapy Training Program will be open to interested healthcare professionals on both sides of the Canada-United States border.

In planning to expand from a local to national initiative, ATMA has signed Letters of Intent (LOIs) with multiple organizations that have the appropriate clinical facilities and staff to support this Canada-wide clinical trial. Having local support sites will ensure that the trial will service healthcare professionals from coast-to-coast in a logistical and efficient manner. David Harder adds, “We welcome more physician, clinician, and clinic participation in this historic collaboration of the largest psilocybin clinical trial to date. Physicians, clinicians, and clinics looking to explore psilocybin-assisted therapy as part of their future service offerings could benefit greatly from this trial.”

It is important for ATMA to collaborate with multiple capable organizations across Canada in order to conduct and maintain the integrity of this large Phase II clinical trial, as well as larger subsequent clinical trials. ATMA is pleased to have established such like-minded partnerships in an effort to bring these trials to healthcare professionals across Canada, allowing for individuals to participate locally without a travel burden added to their already busy schedules.ABOUT ATMA JOURNEY CENTERS INC.

ATMA is pioneering a therapist-centered and therapist-driven business model for the psychedelic industry, by building the largest online community platform for psychedelic practitioners. Education, training, and business support services will all be accessible on one user friendly technology platform. Our philosophy of inclusivity will encourage more participation from healthcare professionals, which will in turn yield more data and experiences. Overall, this will lead to increased effectiveness and accessibility of psychedelic-assisted therapy. Beginning with a clear focus on psilocybin-assisted therapy, we will be able to expand to other psychedelics as the regulatory environment also expands. ATMA provides a clear, guided path for healthcare professionals and clinics to build psychedelic-assisted therapies into their current practices.

SOURCE ATMA Journey Centers Inc

For further information: MEDIA CONTACT: David Harder, Co-CEO, ATMA Journey Centers Inc., david@atmajourney.com

Posted on

Participate in psychedelic research

If you’ve been wanting to try psychedelic therapy legally, now’s your chance!

Johns Hopkins is recruiting participants for a number of psilocybin studies on:

Plus, Nova Mentis is recruiting both autisitc and neurotypical patients for an observational study that will lead to a psilocybin microdosing study.

If you want to contribute to psychedelic research from home, check out Johns Hopkins’ online surveys on psychedelics and breathwork for anxiety, depression, and PTSD.

Posted on

Unsatisfied with life?

A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological symptoms

A Maastricht University study found that a single dose of 5-MeO-DMT (the psychedelic found in toad venom and several plants) improved subjects’ scores for life satisfaction, depression, anxiety, and mindfulness. 

The changes were seen 1 day after the dose and persisted for 4 weeks.

Higher levels of ego dissolution were linked with greater improvements in scores (so, the more intense the trip, the more beneficial).

A separate survey found that ~80% of people with depression or anxiety reported improvements in symptoms following a dose of 5-MeO-DMT.

Some companies that are researching 5-MeO-DMT include GH Research (GHRS), Biomind Labs (BMND), and Mindset Pharma (MSET).

PDF of article

PDF of study

Posted on

Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder

Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder

Wesana Health (WESA) may expand the indication of its psilocybin formulation after meeting with the FDA. In addition to treating anxiety related to traumatic brain injury, it could also target depression. A $3M private placement will fund phase Ib/IIa depression study next year.

PDF of article

Posted on

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

– “LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy” will present the most recent and robust data on LSD in patients with anxiety –

– This study builds on decades of research on the effects of LSD in humans –

NEW YORK, April 14, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti, MindMed collaborators at University Hospital Basel (UHB), will present results from the LSD-Assist Study, a Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders, at London’s PSYCH Symposium on May 11, 2022. 

The presentation, titled “LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy”, will present preliminary topline safety and efficacy results for lysergic acid diethylamide (LSD) in 46 patients with clinically significant anxiety. The trial was conducted at two centers, at UHB and at the private psychiatry practice of Dr. Peter Gasser. MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for LSD and other novel therapies and has exclusive access and rights to the data generated by these studies.

Prof. Dr. Liechti said, “Anxiety disorders are widespread and often insufficiently managed with available medications. I look forward to sharing the preliminary findings from this important study, including patients with anxiety associated with life-threatening illness but also patients with anxiety disorder without severe somatic illness, adding to our understanding of how LSD may be used safely to treat anxiety disorders.”

“Since the 1940s, LSD has been extensively investigated for its effects in humans, showing particular benefit in mitigating symptoms of anxiety and depression,” added Robert Barrow, Chief Executive Officer and Director of MindMed. “The results from this study, if positive, would further validate our approach to develop MM-120 in the treatment of Generalized Anxiety Disorder and would support the progression of our MM-120 development program. We are proud to support Dr. Liechti and his team and to extend their findings through our commercial drug development programs.”

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. 

For Media: media@mindmed.co

For Investors: ir@mindmed.co